The FDA-cleared version of PrecivityAD2 is now available for clinicians to order for adults ages 40 and older with cognitive symptoms.


C2N Diagnostics says health care professionals can now order the FDA-cleared version of its PrecivityAD2 blood test, which the company describes as the first FDA-cleared Alzheimer’s test for adults with cognitive symptoms as young as 40 years.

The test uses high-resolution mass spectrometry to measure %p-tau217 and Aβ42/40. A proprietary algorithm then combines the two biomarkers to calculate the Amyloid Probability Score 2. The score indicates the likelihood of brain amyloid pathology, a pathological hallmark of Alzheimer’s disease.

The test can aid in ruling in or ruling out brain amyloid pathology across primary and specialized care settings. It is intended for use by clinicians experienced in evaluating cognitive impairment. According to the company, results can help clinicians evaluate symptomatic patients and determine next steps, including potential disease-modifying treatment options.

Validation Across Patient Characteristics

C2N reports that the test was validated across clinical characteristics including age, sex, and disease stage. The company also says it demonstrates consistent performance across common comorbidities, including metabolic, cardiovascular, autoimmune, oncology, mental health, and renal disorders.

“We’ve been waiting for this moment since the FDA initially informed us that its review had cleared the PrecivityAD2 test,” says Joel Braunstein, co-founder, CEO, and president of C2N Diagnostics, in a release. “The availability of the PrecivityAD2 test across the country through health care professionals means patients and families will have a clearer picture of brain amyloid plaque.”

Braunstein adds that the test should help “streamline and simplify the complex diagnostic pathway that many patients face when dealing with serious memory concerns.”

Timely Detection

Michael Brown, director of the Alliance to Improve Dementia Care, a program of the Milken Institute’s Future of Aging and Longevity, points to the time-sensitive nature of diagnosis.

“Early and accurate detection matters when each day an estimated 2,000 to 3,000 Medicare beneficiaries with Alzheimer’s disease pathology progress beyond the window of approved disease-modifying therapies,” says Brown, in a release. Those therapies are indicated for mild cognitive impairment and mild dementia due to Alzheimer’s disease.

In its latest report on the topic, the institute urges health care systems to quickly and efficiently adopt well-validated blood biomarkers as the standard of care for patients with signs and symptoms of cognitive decline.

Chris Cronin, 60, of Ballwin, Missouri, took an earlier version of the Precivity test after his wife and sister noticed memory issues. “It has given me the opportunity to start treatment for early-onset Alzheimer’s much sooner than I could have without the Precivity blood test,” says Cronin, in a release.

C2N says its assays have been used in more than 200 Alzheimer’s disease and other research studies in the US and worldwide. The company also reports that more than 90,000 Precivity-related biomarker measures have been reported through peer-reviewed publications.

ID 486365241 © Prostockstudio | Dreamstime.com